Addiction Treatment Access: What Research Shows About the Gap Between Need and Care

Substance use disorders affect tens of millions of Americans, yet the vast majority of those who need treatment do not receive it. Data from the Substance Abuse and Mental Health Services Administration consistently finds that fewer than 20 percent of people with substance use disorders receive any form of specialty treatment in a given year. This treatment gap represents an enormous burden of preventable suffering and death, particularly in the context of the opioid overdose epidemic that has killed hundreds of thousands of Americans over the past two decades. Research on what drives the gap and what interventions show the greatest promise for closing it provides a basis for evidence-informed policy. The reasons people with substance use disorders do not receive treatment are multiple and interact in complex ways. Stigma is among the most pervasive barriers. Substance use disorders carry social stigma that is not matched for most other chronic medical conditions, and research finds that stigma is internalized by individuals with these disorders, producing shame and reluctance to seek help. Provider stigma, meaning negative attitudes among healthcare professionals toward patients with substance use disorders, further reduces the quality and availability of care. Research on stigma reduction interventions finds that framing addiction as a chronic brain disease rather than a moral failing can reduce some dimensions of stigma, though deep attitudes change slowly. Insurance coverage gaps have historically limited access to addiction treatment. The Mental Health Parity and Addiction Equity Act of 2008 requires that insurance coverage for substance use disorders be comparable to coverage for physical health conditions, but enforcement has been inconsistent and legal challenges about what constitutes parity continue. Research finds ongoing disparities between coverage for addiction treatment and coverage for other medical conditions, including higher prior authorization requirements, stricter utilization management, and narrower networks for behavioral health services. The availability of treatment providers is a fundamental constraint, particularly in rural areas and communities with high proportions of uninsured or Medicaid-enrolled individuals. Specialty substance use disorder treatment programs are concentrated in urban areas and in communities with resources to support them. Rural communities frequently lack residential treatment options and may have few or no outpatient providers. Research on geographic access to treatment finds that distance is a significant deterrent to treatment seeking and retention. Medications for opioid use disorder, including buprenorphine and methadone, represent the most effective treatment available for opioid addiction and dramatically reduce overdose mortality. Yet access to these medications has been severely restricted by regulatory requirements. Methadone for opioid use disorder can only be dispensed in federally licensed opioid treatment programs, requiring daily clinic visits that create substantial logistical barriers. Buprenorphine can be prescribed in office-based settings but required a specific Drug Enforcement Administration waiver, known as the X-waiver, for more than two decades. Research finds that X-waiver requirements substantially reduced the number of providers willing to prescribe buprenorphine, particularly in rural areas. The waiver requirement was eliminated in 2023, removing one significant barrier to access. Telemedicine prescribing of buprenorphine, which expanded dramatically during the COVID-19 pandemic under emergency regulatory waivers, has been associated with increased treatment initiation and retention in research conducted during the waiver period. Studies comparing outcomes for patients who initiated treatment via telemedicine versus in-person find comparable retention and outcomes, with some evidence that telemedicine serves populations including rural patients and those with transportation barriers who would not have otherwise accessed treatment. The status of telehealth prescribing for controlled substances after the pandemic emergency period has been a subject of policy debate. Stigma within healthcare settings manifests in specific ways that research has documented. Studies using standardized patient approaches find that patients identifying as having opioid use disorder receive different quality of care than other patients presenting with comparable medical needs. Emergency department practices around patients presenting with overdose frequently fail to offer medication-assisted treatment initiation or warm handoffs to outpatient care, representing a missed opportunity at a moment of crisis motivation. Recovery support services, including peer support specialists who have personal experience with addiction recovery, recovery housing, and employment support, are recognized components of comprehensive treatment systems. Research on peer support finds that people with lived experience of addiction and recovery can effectively provide navigation, support, and motivation to individuals in treatment and recovery in ways that professionally trained but not personally experienced providers cannot replicate. Medicaid coverage for peer support services has expanded in many states, making this workforce more sustainable. Prevention and harm reduction are adjacent to treatment access but interact with it in important ways. Research finds that harm reduction services, including needle exchanges and naloxone distribution, create contact points between people who use drugs and social service systems, increasing the probability of eventual treatment engagement. Communities that invest in harm reduction alongside treatment access show better outcomes across multiple indicators than those that treat these as alternative approaches. Closing the treatment gap for substance use disorders requires simultaneous action on multiple fronts: reducing stigma in communities and healthcare settings, expanding insurance coverage and enforcement of parity requirements, growing the provider workforce through training and financing incentives, expanding access to medications including through telemedicine and relaxed prescribing requirements, and investing in recovery support services. Research provides guidance on which of these approaches are most evidence-based, but the political will to make the necessary investments remains the binding constraint.